Startup Funding News
Explore funding rounds, the companies behind them and the investors taking part.
- Rounds
- 4,718 Jan 1 – Oct 25, 2026
- Disclosed funding
- $341.9B 3676 disclosed amounts
- Median round
- $14.6M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| P ParlayXCompany profile ParlayX provides institutional trading desks with a shared control and execution layer for prediction markets, including segregated capital, trader and bot permissions, non-custodial key management and order routing across venues. ParlayX provides institutional trading desks with a shared control and execution layer for prediction markets, including segregated capital, trader and bot permissions, non-custodial key management and order routing across venues. | $1.3M | Pre-SeedPre-seed | Fintech | United States | Investors | |
| SS Sorry SugarCompany profile A beverage brand selling monk-fruit-sweetened coffee mixes and café drinks with no added sugar. A beverage brand selling monk-fruit-sweetened coffee mixes and café drinks with no added sugar. | $1M | Seed | Foodtech | India | Investors | |
Gimlet LabsCompany profile Provides a cloud inference platform and compiler that distribute AI workloads across different processor types. Provides a cloud inference platform and compiler that distribute AI workloads across different processor types. | $300M | Series B | AI | United States | Investors | |
| CB Cloverleaf BioCompany profile Cloverleaf Bio is developing engineered transfer RNA therapies that use a modified tRNA payload to inhibit cancer cells' RNA-modifying enzymes. Its lead program targets liver cancer and is advancing toward clinical testing; a second antibody-tRNA program for colorectal cancer remains preclinical. Cloverleaf Bio is developing engineered transfer RNA therapies that use a modified tRNA payload to inhibit cancer cells' RNA-modifying enzymes. Its lead program targets liver cancer and is advancing toward clinical testing; a second antibody-tRNA program for colorectal cancer remains preclinical. | $33M | Seed | Biotech | United States | Investors | |
| AR ARC RideCompany profile ARC Ride supplies electric motorcycles and battery-swapping services for commercial riders and fleet operators. ARC Ride supplies electric motorcycles and battery-swapping services for commercial riders and fleet operators. | $33.3M | FundingUndisclosed | Mobility | Kenya | Investors | |
MagnarCompany profile Legal AI software that helps lawyers research law and prepare work grounded in jurisdiction-specific sources. Legal AI software that helps lawyers research law and prepare work grounded in jurisdiction-specific sources. | $8M | Series A | Enterprise software | Chile | Investors | |
Yngvi BioCompany profile A Copenhagen crop-protection biotech developing protein-based pest-control products designed to target specific agricultural pests while reducing harm to beneficial insects and reliance on conventional pesticides. A Copenhagen crop-protection biotech developing protein-based pest-control products designed to target specific agricultural pests while reducing harm to beneficial insects and reliance on conventional pesticides. | €1.3M | BII Venture House convertible loanUndisclosed | Agritech | Denmark | Investors | |
| A AntiochCompany profile Cloud simulation software helps robotics and autonomy teams develop and test physical AI systems before deployment. Cloud simulation software helps robotics and autonomy teams develop and test physical AI systems before deployment. | $32M | Series A | AI | United States | Investors | |
Hope CareCompany profile Hope Care provides a regulated remote-patient-monitoring platform to health systems and care providers. Its OpMA platform brings patient-reported and connected-device measurements into clinical programmes, where care teams review dashboards and alerts, follow patients remotely and intervene when readings indicate deterioration. Hope Care provides a regulated remote-patient-monitoring platform to health systems and care providers. Its OpMA platform brings patient-reported and connected-device measurements into clinical programmes, where care teams review dashboards and alerts, follow patients remotely and intervene when readings indicate deterioration. | €6M | Series A | Healthtech | Portugal | Investors | |
| E EmberosCompany profile Emberos gives brands a system to track how AI assistants represent them, understand the sources and narratives behind those answers, and take and measure actions intended to improve their visibility and accuracy across AI platforms. Emberos gives brands a system to track how AI assistants represent them, understand the sources and narratives behind those answers, and take and measure actions intended to improve their visibility and accuracy across AI platforms. | $5.5M | Seed | Enterprise software | United States | Investors Undisclosed |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jan 1, 2026
- 1Y Combinator (YC)
BioStack, Tractian, Blacksmith
161rounds5led - 2Andreessen Horowitz (a16z)
ASI, Eka Robotics, Town
112rounds22led - 3General Catalyst
Tractian, Legora, Different
100rounds12led - 4Lightspeed
Warp Sciences, Different, Zenzap
80rounds9led - 5Sequoia Capital
Warhound, Whop, Blacksmith
71rounds13led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.
Browse rounds by topic
Geography
Featured selections
Nordic Foodtech Fund II pairs early capital with scientific expertise
An EIF pledge of up to €30m supports a fund targeting €80m for science-led agrifood companies.
Read the research →